-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Opioid use disorder is a chronic, debilitating and expensive disorder
Opioid use disorder is a chronic, debilitating and expensive disorder
Researchers conducted a practical, open-label randomized controlled trial at the British National Health Service Specialty Addiction Clinic in London, England
Researchers conducted a practical, open-label randomized controlled trial at the British National Health Service Specialty Addiction Clinic in London, England
Survey, 2013 Nian 6 Yue 7 to 2015 Nian 12 Yue 21 the date, researchers randomly assigned 136 participants into the psychosocial intervention group, 137 participants assigned to the control group
Survey, 2013 Nian 6 Yue 7 to 2015 Nian 12 Yue 21 the date, researchers randomly assigned 136 participants into the psychosocial intervention group, 137 participants assigned to the control group
Studies have shown that, in addition to standard treatment, in maintaining opioid receptor agonist treatment, assisted personalized psychosocial intervention is compared with standard treatment alone, in helping treatment-resistant patients avoid the use of illegal and over-the-counter opioids and cocaine.
Studies have shown that, in addition to standard treatment, in maintaining opioid receptor agonist treatment, assisted personalized psychosocial intervention is compared with standard treatment alone, in helping treatment-resistant patients avoid the use of illegal and over-the-counter opioids and cocaine.
Original source:
Original source:Prof John Marsden, PhD, Efficacy andcost-effectiveness of an adjunctive personalised psychosocial intervention intreatment-resistant maintenance opioid agonist therapy: a pragmatic,open-label, randomised controlled trial
Prof John Marsden, PhD, Efficacy andcost-effectiveness of an adjunctive personalised psychosocial intervention intreatment-resistant maintenance opioid agonist therapy: a pragmatic,open-label, randomised controlled trialEfficacy andcost-effectiveness of an adjunctive personalised psychosocial intervention intreatment-resistant maintenance opioid agonist therapy: a pragmatic,open-label, randomised controlled trialThis article is Metz Medicine ( MedSci ) original finishing compiler, Reprinted with authorization!
This article is Metz Medicine ( MedSci ) original finishing compiler, Reprinted with authorization!
Leave a message here
